Company intelligence / Profile preview

Cardialen

Minneapolis, Minnesota, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

Cardialen developed MultiPulse Therapy™, an implantable device-based platform delivering ultra-low-energy pulses for the cardioversion and defibrillation of atrial fibrillation and ventricular tachycardia. Clinical studies demonstrated the potential for pain-free or minimally perceptible restoration of normal heart rhythm. The technology was acquired by Maxwell Biomedical in December 2022 to complement their own cardiac rhythm management portfolio.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapyImplantable medical device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Cardialen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardialen.

Explore the full profile